Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Operating Leases (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Operating Leases for 6 consecutive years, with $28.7 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 32.92% to $28.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, down 32.92% year-over-year, with the annual reading at $28.7 million for FY2025, 32.92% down from the prior year.
  • Operating Leases for Q4 2025 was $28.7 million at Relay Therapeutics, down from $29.7 million in the prior quarter.
  • The five-year high for Operating Leases was $54.6 million in Q3 2022, with the low at $20.0 million in Q2 2022.
  • Average Operating Leases over 5 years is $37.4 million, with a median of $42.0 million recorded in 2024.
  • The sharpest move saw Operating Leases surged 155.25% in 2023, then tumbled 33.01% in 2025.
  • Over 5 years, Operating Leases stood at $21.1 million in 2021, then surged by 153.92% to $53.5 million in 2022, then dropped by 9.28% to $48.5 million in 2023, then dropped by 11.81% to $42.8 million in 2024, then crashed by 32.92% to $28.7 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $28.7 million, $29.7 million, and $30.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.